KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Assets (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Non-Current Assets data on record, last reported at $409.0 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 46.52% year-over-year to $409.0 million; the TTM value through Dec 2025 reached $1.6 billion, down 53.04%, while the annual FY2025 figure was $409.0 million, 46.52% down from the prior year.
  • Non-Current Assets reached $409.0 million in Q4 2025 per PACB's latest filing, roughly flat from $408.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.0 billion in Q3 2023 and bottomed at $56.6 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $727.8 million, with a median of $904.7 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: soared 1499.18% in 2022, then crashed 58.12% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $905.8 million in 2021, then rose by 1.01% to $915.0 million in 2022, then increased by 9.72% to $1.0 billion in 2023, then fell by 23.83% to $764.8 million in 2024, then crashed by 46.52% to $409.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $409.0 million in Q4 2025, $408.9 million in Q3 2025, and $412.1 million in Q2 2025.